- Home
- PENG vs GHRS Comparison
PENG vs GHRS Comparison
Compare PENG & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | GHRS |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | Ireland |
| Employees | 2900 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 947.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PENG | GHRS |
|---|---|---|
| Price | $52.93 | $22.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $27.78 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 3.0M | 193.2K |
| Earning Date | 04-01-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.55 | N/A |
| Revenue Next Year | $16.14 | N/A |
| P/E Ratio | $87.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.04 | $10.96 |
| 52 Week High | $53.27 | $24.66 |
Technical Indicators
Market Signals| Indicator | PENG | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 81.38 | 61.36 |
| Support Level | $19.31 | $12.65 |
| Resistance Level | $53.27 | $22.88 |
| Average True Range (ATR) | 4.23 | 1.49 |
| MACD | 0.42 | -0.13 |
| Stochastic Oscillator | 92.15 | 58.59 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.